Research ArticleAccepted Article
Open Access
Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases
Marco Fornaro, Vincenzo Venerito, Florenzo Iannone and Fabio Cacciapaglia
The Journal of Rheumatology January 2022, jrheum.210863; DOI: https://doi.org/10.3899/jrheum.210863
Marco Fornaro
Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy. Conflicts of interest/Competing interests: The authors declare they have no conflict of interest regarding the present work. Statement of ethics: Data collection for this study was approved by local ethic committee (study n. 5277, approval n. 83233, 09/08/2017, email: comitatoetico@policlinico.ba.it). Consent: Patients written informed consent to participate in the study was obtained. Corresponding author: Florenzo Iannone, Department of Emergency and Organ Transplantation – Rheumatology Unit, Piazza G Cesare, 11 70124 Bari, Italy. Email florenzo.iannone@uniba.it
Vincenzo Venerito
Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy. Conflicts of interest/Competing interests: The authors declare they have no conflict of interest regarding the present work. Statement of ethics: Data collection for this study was approved by local ethic committee (study n. 5277, approval n. 83233, 09/08/2017, email: comitatoetico@policlinico.ba.it). Consent: Patients written informed consent to participate in the study was obtained. Corresponding author: Florenzo Iannone, Department of Emergency and Organ Transplantation – Rheumatology Unit, Piazza G Cesare, 11 70124 Bari, Italy. Email florenzo.iannone@uniba.it
Florenzo Iannone
Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy. Conflicts of interest/Competing interests: The authors declare they have no conflict of interest regarding the present work. Statement of ethics: Data collection for this study was approved by local ethic committee (study n. 5277, approval n. 83233, 09/08/2017, email: comitatoetico@policlinico.ba.it). Consent: Patients written informed consent to participate in the study was obtained. Corresponding author: Florenzo Iannone, Department of Emergency and Organ Transplantation – Rheumatology Unit, Piazza G Cesare, 11 70124 Bari, Italy. Email florenzo.iannone@uniba.it
Fabio Cacciapaglia
Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy. Conflicts of interest/Competing interests: The authors declare they have no conflict of interest regarding the present work. Statement of ethics: Data collection for this study was approved by local ethic committee (study n. 5277, approval n. 83233, 09/08/2017, email: comitatoetico@policlinico.ba.it). Consent: Patients written informed consent to participate in the study was obtained. Corresponding author: Florenzo Iannone, Department of Emergency and Organ Transplantation – Rheumatology Unit, Piazza G Cesare, 11 70124 Bari, Italy. Email florenzo.iannone@uniba.it
Article Figures & Data
Additional Files
210863 Video Abstract
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases
Marco Fornaro, Vincenzo Venerito, Florenzo Iannone, Fabio Cacciapaglia
The Journal of Rheumatology Jan 2022, jrheum.210863; DOI: 10.3899/jrheum.210863
Accepted manuscript
Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases
Marco Fornaro, Vincenzo Venerito, Florenzo Iannone, Fabio Cacciapaglia
The Journal of Rheumatology Jan 2022, jrheum.210863; DOI: 10.3899/jrheum.210863